Successful rapid desensitization to temozolomide: A case series.

Clinical Implications Females (%) 8 (57) Desensitization for temozolomide: primary indication Oligodendroglioma (%) 4 (28) Glioblastoma (%) 3 (21) Glioma (%) 2 (14) Oligoastrocytoma (%) 2 (14) Temozolomide is a first-line therapy for primary brain tumors. Cutaneous hypersensitivity reactions are common and may preclude its use. A protocol for rapid oral desensitization is presented that when used in the correct setting may afford valuable therapy.